Sarah A Best

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4422587/publications.pdf

Version: 2024-02-01

	933447		839539
18	650	10	18
papers	citations	h-index	g-index
19	19	19	1357
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment. Cell Metabolism, 2018, 27, 935-943.e4.	16.2	167
2	Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia. Genes and Development, 2014, 28, 1337-1350.	5.9	73
3	Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma. Nature Communications, 2019, 10, 4190.	12.8	73
4	EGF-mediated induction of Mcl-1 at the switch to lactation is essential for alveolar cell survival. Nature Cell Biology, 2015, 17, 365-375.	10.3	65
5	Glutaminase inhibition impairs CD8 TÂcell activation in STK11-/Lkb1-deficient lung cancer. Cell Metabolism, 2022, 34, 874-887.e6.	16.2	55
6	Harnessing Natural Killer Immunity in Metastatic SCLC. Journal of Thoracic Oncology, 2020, 15, 1507-1521.	1.1	50
7	"Keaping―a lid on lung cancer: the Keap1-Nrf2 pathway. Cell Cycle, 2018, 17, 1696-1707.	2.6	39
8	Dual roles for Id4 in the regulation of estrogen signaling in the mammary gland and ovary. Development (Cambridge), 2014, 141, 3159-3164.	2.5	30
9	Lung morphogenesis is orchestrated through Grainyhead-like 2 (Grhl2) transcriptional programs. Developmental Biology, 2018, 443, 1-9.	2.0	21
10	CCAR2 Is Required for Proliferation and Tumor Maintenance in Human Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2017, 137, 506-512.	0.7	17
11	An Integrated Molecular Grafting Approach for the Design of Keap1-Targeted Peptide Inhibitors. ACS Chemical Biology, 2021, 16, 1276-1287.	3.4	11
12	BCKDK alters the metabolism of non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 4459-4476.	2.8	11
13	FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium. Oncogene, 2018, 37, 6096-6104.	5.9	10
14	Combining Cell Type-Restricted Adenoviral Targeting with Immunostaining and Flow Cytometry to Identify Cells-of-Origin of Lung Cancer. Methods in Molecular Biology, 2018, 1725, 15-29.	0.9	9
15	Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis. Cell Death and Disease, 2020, 11, 877.	6.3	7
16	Absence of pro-survival A1 has no impact on inflammatory cell survival in vivo during acute lung inflammation and peritonitis. Cell Death and Differentiation, 2022, 29, 96-104.	11.2	7
17	Exploring natural killer cell immunology as a therapeutic strategy in lung cancer. Translational Lung Cancer Research, 2021, 10, 2788-2805.	2.8	3
18	Characterization of a novel human BFL-1-specific monoclonal antibody. Cell Death and Differentiation, 2020, 27, 826-828.	11.2	2